Vaccinex, Inc.
VCNX · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $0 | $1 |
| % Growth | 5.4% | 470% | -88.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1 | $1 | $0 | $1 |
| % Margin | 100% | 100% | 68% | 81.2% |
| R&D Expenses | $13 | $17 | $14 | $17 |
| G&A Expenses | $7 | $7 | $6 | $6 |
| SG&A Expenses | $7 | $7 | $6 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$0 | -$0 |
| Operating Expenses | $19 | $23 | $20 | $23 |
| Operating Income | -$19 | -$23 | -$20 | -$22 |
| % Margin | -3,117.3% | -4,014.9% | -19,906% | -2,498.9% |
| Other Income/Exp. Net | $0 | $3 | $0 | $0 |
| Pre-Tax Income | -$19 | -$20 | -$20 | -$22 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$19 | -$20 | -$20 | -$22 |
| % Margin | -3,100.5% | -3,552.8% | -19,722% | -2,486.7% |
| EPS | -8.88 | -43.68 | -97.59 | -163.8 |
| % Growth | 79.7% | 55.2% | 40.4% | – |
| EPS Diluted | -8.88 | -43.68 | -97.59 | -162.91 |
| Weighted Avg Shares Out | 2 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 2 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$19 | -$20 | -$20 | -$21 |
| % Margin | -3,084.5% | -3,464.6% | -19,606% | -2,378% |